Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 10/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479334 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2ENPP2LPAR2TDP1 | |
| SCHEMBL4476952 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2ENPP2LPAR2TDP1 | |
| SCHEMBL17253399 | 0.87 | ALDH1A1 (0.57) | ALDH1A1TDP1 | |
| SCHEMBL18327147 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 | |
| SCHEMBL5839131 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 | |
| SCHEMBL9234691 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 | |
| SCHEMBL30958398 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 | |
| SCHEMBL18327140 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 | |
| SCHEMBL5839128 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 | |
| SCHEMBL10770166 | 0.83 | ALDH1A1 (0.76) | ALDH1A1ENPP2LPAR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612106-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-1831178-A2 | FUSED PYRAZOLE DERIVATIVES AND USES THEREOF IN METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006069242-A2 | FUSED PYRAZOLE DERIVATIVES AND USES THEREOF IN METHODS OF TREATMENT OF METABOLIC-RELATED?DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ACE, ACE2, AGTR2 | ALDH1A1 794/4885SMN1; SMN2 4507/4885ENPP2 415/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | ALDH1A1 794/4885SMN1; SMN2 4507/4885ENPP2 415/4885 |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | ALDH1A1 794/4885SMN1; SMN2 4507/4885ENPP2 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.